87 related articles for article (PubMed ID: 9203827)
1. Dynamic compatibility testing of DMP 840, an experimental antitumor agent.
Rubino JT; Nellore R; Parmar B
PDA J Pharm Sci Technol; 1997; 51(3):130-6. PubMed ID: 9203827
[TBL] [Abstract][Full Text] [Related]
2. Solubility enhancement of a bisnaphthalimide tumoricidal agent, DMP 840, through complexation.
Raghavan KS; Nemeth GA; Gray DB; Hussain MA
Pharm Dev Technol; 1996 Oct; 1(3):231-8. PubMed ID: 9552305
[TBL] [Abstract][Full Text] [Related]
3. Compatibility and stability of the novel anti-cancer agent C1311 in infusion devices and its in vitro biocompatibility.
den Brok MW; Nuijen B; Harms R; Buluran JN; Harvey MD; Grieshaber CK; Beijnen JH
J Oncol Pharm Pract; 2005 Mar; 11(1):13-9. PubMed ID: 16460599
[TBL] [Abstract][Full Text] [Related]
4. Drug Crystal Precipitation in Biorelevant Bicarbonate Buffer: A Well-Controlled Comparative Study with Phosphate Buffer.
Yamamoto H; Sugano K
Mol Pharm; 2024 Jun; 21(6):2854-2864. PubMed ID: 38718215
[TBL] [Abstract][Full Text] [Related]
5. Reformulation of a new vancomycin analog: an example of the importance of buffer species and strength.
Johnson JL; Yalkowsky SH
AAPS PharmSciTech; 2006 Jan; 7(1):E5. PubMed ID: 16584164
[TBL] [Abstract][Full Text] [Related]
6. Photoinduced particulate matter in a parenteral formulation for bisnafide, an experimental antitumor agent.
Rubino JT; Chan LL; Walker JT; Segretario J; Everlof JG; Hussain MA
Pharm Dev Technol; 1999 Aug; 4(3):439-47. PubMed ID: 10434290
[TBL] [Abstract][Full Text] [Related]
7. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
Kirshenbaum MR; Chen SF; Behrens CH; Papp LM; Stafford MM; Sun JH; Behrens DL; Fredericks JR; Polkus ST; Sipple P
Cancer Res; 1994 Apr; 54(8):2199-206. PubMed ID: 8174127
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
[TBL] [Abstract][Full Text] [Related]
9. The impact of multilumen infusion devices on the occurrence of known physical drug incompatibility: a controlled in vitro study.
Foinard A; Décaudin B; Barthélémy C; Debaene B; Odou P
Anesth Analg; 2013 Jan; 116(1):101-6. PubMed ID: 23223095
[TBL] [Abstract][Full Text] [Related]
10. Compatibility of aminophylline and verapamil in intravenous admixtures.
Johnson CE; Lloyd CW; Mesaros JL; Rubley GJ
Am J Hosp Pharm; 1989 Jan; 46(1):97-100. PubMed ID: 2712035
[TBL] [Abstract][Full Text] [Related]
11. Solubility-pH profile of desipramine hydrochloride in saline phosphate buffer: Enhanced solubility due to drug-buffer aggregates.
Marković OS; Pešić MP; Shah AV; Serajuddin ATM; Verbić TŽ; Avdeef A
Eur J Pharm Sci; 2019 May; 133():264-274. PubMed ID: 30914359
[TBL] [Abstract][Full Text] [Related]
12. Aluminum elution and precipitation in glass vials: effect of pH and buffer species.
Ogawa T; Miyajima M; Wakiyama N; Terada K
Drug Dev Ind Pharm; 2015 Feb; 41(2):315-21. PubMed ID: 24261406
[TBL] [Abstract][Full Text] [Related]
13. In vitro hemolysis and buffer capacity studies with the novel marine anticancer agent kahalalide F and its reconstitution vehicle cremophor EL/ethanol.
Nuijen B; Bouma M; Manada C; Jimeno JM; Bult A; Beijnen JH
PDA J Pharm Sci Technol; 2001; 55(4):223-9. PubMed ID: 11505554
[TBL] [Abstract][Full Text] [Related]
14. Solution-mediated phase transformation of salts during dissolution: investigation using haloperidol as a model drug.
Greco K; Mcnamara DP; Bogner R
J Pharm Sci; 2011 Jul; 100(7):2755-68. PubMed ID: 21328581
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of osmolality and pH of various concentrations of methotrexate, cytarabine, and thiotepa prepared in normal saline, sterile water for injection, and lactated Ringer's solution for intrathecal administration.
de Lemos ML; Monfared S; Denyssevych T; Hamata L; Jennings S; Thiessen B; Smith S; Waterhouse D
J Oncol Pharm Pract; 2009 Mar; 15(1):45-52. PubMed ID: 18772215
[TBL] [Abstract][Full Text] [Related]
16. Buffer capacity and precipitation control of pH solubilized phenytoin formulations.
Alvarez-Núñez FA; Yalkowsky SH
Int J Pharm; 1999 Aug; 185(1):45-9. PubMed ID: 10425364
[TBL] [Abstract][Full Text] [Related]
17. A dynamic system for the simulation of fasting luminal pH-gradients using hydrogen carbonate buffers for dissolution testing of ionisable compounds.
Garbacz G; Kołodziej B; Koziolek M; Weitschies W; Klein S
Eur J Pharm Sci; 2014 Jan; 51():224-31. PubMed ID: 24095865
[TBL] [Abstract][Full Text] [Related]
18. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of in vitro precipitation methods.
Li P; Vishnuvajjala R; Tabibi SE; Yalkowsky SH
J Pharm Sci; 1998 Feb; 87(2):196-9. PubMed ID: 9519153
[TBL] [Abstract][Full Text] [Related]
20. Estimation of drug precipitation upon dilution of pH-controlled formulations.
Narazaki R; Sanghvi R; Yalkowsky SH
Mol Pharm; 2007; 4(4):550-5. PubMed ID: 17530775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
